Eribulin mesilate

DRUG2 trials

Sponsors

Swiss Cancer Institute, Eisai Inc.

Conditions

AdenocarcinomaBreast CancerEwing SarcomaNon-Rhabdomyosarcoma Soft Tissue SarcomaRefractory or Recurrent Solid TumorsRhabdomyosarcoma

Phase 1

Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors

CompletedNCT03245450

Eisai Inc.Ewing Sarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Refractory or Recurrent Solid Tumors +1

Start: 2018-03-05End: 2021-05-17Updated: 2022-06-28

Phase 2

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

TerminatedNCT02404506

Swiss Cancer InstituteAdenocarcinoma, Breast Cancer

Start: 2015-08-17End: 2021-07-22Updated: 2021-09-29

Related Papers

A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors.

Journal of Clinical Oncology2020-05-202 citations

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes

Japanese Journal of Clinical Oncology2019-06-1224 citations